pipotiazine pipotiazine pipotiazine (piportil), also known as pipothiazine, is a typical antipsychotic of the phenothiazine class used in the united kingdom and other countries for the treatment of schizophrenia. its properties are similar to those of chlorpromazine. a 2004 systematic review investigated its efficacy for people with schizophrenia: pipotiazine palmitate compared to oral antipsychotics for schizophrenia summary although well-conducted and reported randomized trials are still needed to fully inform practice (no trial data exists reporting hospital and services outcomes, quality of life, satisfaction with care and economics) pipotiazine palmitate is a viable choice for both clinician and person with schizophrenia. outcome findings in words findings in numbers quality of evidence global outcomes no important clinical responsefollow-up: by 3 week)there is no clear difference between people given pipotiazine palmitate and those receiving oral antipsychotics. these findings are based on data of low quality.rr 2.57 (0.76 to 8.63)low leaving the study earlyfollow-up: up to 5 weekspipotiazine palmitate may increase the chance of leaving the study early but the difference between people given pipotiazine palmitate and those receiving oral antipsychotics is not clear. these findings are based on data of low quality.rr 3.85 (0.46 to 32.22)low mental state relapsefollow-up: by 18 months)pipotiazine palmitate has not more - or less - effect on risk of relapse than oral antipsychotics. these findings are based on data of low quality.rr 1.55 (0.76 to 3.18)low adverse effects tardive dyskinesiaoral antipsychotic drugs and pipotiazine palmitate carry similar risks of this problematic movement disorder. these findings are based on data of low quality.rr 1.03 (0.22 to 4.92)low dystoniapipotiazine palmitate may slightly reduce the chance of experiencing this movement disorder but there is no clear difference between people given pipotiazine palmitate and those receiving oral antipsychotics. these findings are based on data of low quality. rr 0.32 (0.04 to 2.89)low pharmacokinetics of long-acting injectable antipsychotics medicationbrand nameclassvehicledosagetmaxt1/2 singlet1/2 multiplelogpcref aripiprazole lauroxilaristadaatypicalwatera441–1064 mg/4–8 weeks24–35 days ?54–57 days7.9–10.0 aripiprazole monohydrateabilify maintenaatypicalwatera300–400 mg/4 weeks7 days ?30–47 days4.9–5.2 bromperidol decanoateimpromen decanoastypicalsesame oil40–300 mg/4 weeks3–9 days ?21–25 days7.9 clopentixol decanoatesordinol depottypicalviscoleob50–600 mg/1–4 weeks4–7 days ?19 days9.0 flupentixol decanoatedepixoltypicalviscoleob10–200 mg/2–4 weeks4–10 days8 days17 days7.2–9.2 fluphenazine decanoateprolixin decanoatetypicalsesame oil12.5–100 mg/2–5 weeks1–2 days1–10 days14–100 days7.2–9.0 fluphenazine enanthateprolixin enanthatetypicalsesame oil12.5–100 mg/1–4 weeks2–3 days4 days ?6.4–7.4 fluspirileneimap, redeptintypicalwatera2–12 mg/1 week1–8 days7 days ?5.2–5.8 haloperidol decanoatehaldol decanoatetypicalsesame oil20–400 mg/2–4 weeks3–9 days18–21 days7.2–7.9 olanzapine pamoatezyprexa relprevvatypicalwatera150–405 mg/2–4 weeks7 days ?30 days– oxyprothepin decanoatemeclopintypical ? ? ? ? ?8.5–8.7 paliperidone palmitateinvega sustennaatypicalwatera39–819 mg/4–12 weeks13–33 days25–139 days ?8.1–10.1 perphenazine decanoatetrilafon dekanoattypicalsesame oil50–200 mg/2–4 weeks ? ?27 days8.9 perphenazine enanthatetrilafon enanthatetypicalsesame oil25–200 mg/2 weeks2–3 days ?4–7 days6.4–7.2 pipotiazine palmitatepiportil longumtypicalviscoleob25–400 mg/4 weeks9–10 days ?14–21 days8.5–11.6 pipotiazine undecylenatepiportil mediumtypicalsesame oil100–200 mg/2 weeks ? ? ?8.4 risperidonerisperdal constaatypicalmicrospheres12.5–75 mg/2 weeks21 days ?3–6 days– zuclopentixol acetateclopixol acuphasetypicalviscoleob50–200 mg/1–3 days1–2 days1–2 days4.7–4.9 zuclopentixol decanoateclopixol depottypicalviscoleob50–800 mg/2–4 weeks4–9 days ?11–21 days7.5–9.0 note: all by intramuscular injection. footnotes: a = microcrystalline or nanocrystalline aqueous suspension. b = low-viscosity vegetable oil (specifically fractionated coconut oil with medium-chain triglycerides). c = predicted, from pubchem and drugbank. sources: main: see template. pipotiazineclinical datatrade namespiportilahfs/drugs.cominternational drug namesroutes ofadministrationoral, imatc coden05ac04 (who) legal statuslegal status in general: ℞ (prescription only) identifiers iupac name 10-propyl]-n,n-dimethyl-phenothiazine-2-sulfonamide cas number39860-99-6pubchem cid62867iuphar/bps7557drugbankdb01621chemspider56598uniil903j9jpyvkeggd08385chemblchembl398880comptox dashboard (epa)dtxsid40192913 echa infocard100.049.672 chemical and physical dataformulac24h33n3o3s2molar mass475.67 g·mol−13d model (jsmol)interactive image smiles cn(c)s(=o)(=o)c1=cc2=c(c=c1)sc3=cc=cc=c3n2cccn4ccc(cc4)cco synthesis patents: sino: the alkylation of 2-dimethylaminosulfonylphenthiazine (1) with 1-bromo-3-chloropropane (2) gives 10-(3-chloropropyl)-n,n-dimethylphenothiazine-2-sulfonamide (3). alkylation with 4-piperidineethanol (4) completes the synthesis of pipothiazine (5).